A Major Development
On August 18, 2025 the European Commission (EC) approved nirogacestat (OGSIVEO®) for adults with progressive desmoid tumors requiring systemic treatment.
This marks the first official approval in Europe of a treatment specifically for desmoid tumors, opening a new chapter in the care of people affected by this rare condition.
What does this mean?
Desmoid tumors are rare, locally aggressive connective tissue growths. Although they do not spread to other organs, their growth and location can cause significant symptoms such as pain, fatigue, and functional limitations. Until recently, no recognized treatment options were available in Europe.
The approval of nirogacestat represents a major scientific and clinical breakthrough: finally, a targeted therapy offering hope to patients, their loved ones, and healthcare providers.
More information can be found via the link below or downloaded here .
Breakthrough for desmoid tumor patients.
NL 
FR 
EN